NCT07080021View on ClinicalTrials.gov

A Cohort Study on ctDNA MRD in Neoadjuvant Therapy for Pancreatic Cancer

RecruitingOBSERVATIONAL
Enrollment

119

Participants

Timeline

Start Date

May 20, 2025

Primary Completion Date

May 20, 2026

Study Completion Date

November 20, 2027

Conditions
Borderline Resectable Pancreatic AdenocarcinomaResectable Pancreatic Adenocarcinoma
Interventions
DRUG

Standard Reagents, Pancreatic Cancer

This is a non-interventional study. Neoadjuvant therapy regimens and surgical approaches are determined solely by attending physicians according to clinical treatment standards.

Trial Locations (2)

Unknown

RECRUITING

Ruijin Hospital Affiliated to Shanghai Jiaotong University School of Medicine, Shanghai

RECRUITING

Ruijin hospital, Shanghai

All Listed Sponsors
lead

Ruijin Hospital

OTHER